Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma. (PubMed, J Clin Exp Hematop) - Jun 29, 2023 - "There were no essential differences in the safety profile of darinaparsin between the Japanese population and the overall population. The results of this subgroup analysis indicate that the efficacy and safety profiles of the Japanese subpopulation were broadly consistent with that of the overall population, and that darinaparsin is potentially an effective treatment with a manageable safety profile in Japanese patients with relapse or refractory PTCL."
Journal • P2 data • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK
|
|
Dai Maruyama; Eiju Negoro; Fumiko Nagahama; Go Yamamoto; Hideaki Nakajima; Hirohiko Shibayama; Hirokazu Nagai; Hwei-Fang Tien; Ilseung Choi; Kazuhito Yamamoto; Kensei Tobinai; Kiyoshi Ando; Koji Izutsu; Nobuhiko Nakamura; Nobuhiro Kanemura; Noriko Fukuhara; Takahiro Yamauchi; Toshiki Uchida; Won-Seog Kim; Yasuhito Terui; Yok-Lam Kwong; Yoshinobu Maeda; Youko Suehiro; Yusuke Sonehara
|